AEGiS-11IAC: Antibody response to tetravalent pneumococcal conjugate vaccine in HIV-infected adults.

11th International AIDS Conference

Vancouver, British Columbia — July 7-12, 1996

Antibody response to tetravalent pneumococcal conjugate vaccine in HIV-infected adults.

Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. We.B.115)
Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R; Dept of Infectious Diseases, University Hospital Leiden, Leiden, The Netherlands. Fax: -31-71-5266758.

INTRODUCTION: HIV-infected individuals have an increased susceptibility to Streptococcus pneumoniae infections. Therefore immunization with the 23-valent polysaccharide vaccine is recommended. This T-lymphocyte independent vaccine elicits an IgG antibody response against the combination of 23 polysaccharides in HIV-infected individuals similar to that in healthy controls (AIDS 1994;8:469-476). Pneumococcal conjugate vaccines are T-cell dependent. This study was undertaken to establish whether the antibody response against a pneumococcal conjugate vaccine (PVC, containing serotype 6B, 14, 19F and 23F [Merck & Co.Inc.]), is impaired during HIV infection.

METHODS: Thirty HIV-infected adults (divided according to CD4+ cell count: is less than or equal to 100 x 106/1 = group I, 101-300 = group II, greater than 300 = group III) and 9 healthy controls were immunized. All received 1 microgram of each capsular polysaccharide at day 1 and 30. IgG antibodies were determined by ELISA. Pre- and postvaccination titres are expressed as geometric mean (GMC) concentrations (microgram/mL).

RESULTS: The antibody response to conjugate pneumococcal vaccine depended on the number of CD4+-lymphocytes. Pre- and postvaccination GMC against all serotypes were significantly lower in group I compared with controls. Postvaccination GMC against 6B, 19F and 23F were significantly lower in group II and in group III compared with controls. (table: see text)

CONCLUSIONS: HIV-infected individuals show low prevaccination antibody concentrations against all investigated pneumococcal serotypes and show an impaired immune response after vaccination.

Keywords: AEGIS, Pneumococcal Vaccines, HIV, Vaccines, Conjugate, Streptococcus pneumoniae, Pneumococcal Infections, Antibody Formation, CD4 Lymphocyte Count, HIV Infections, Vaccination, Acquired Immunodeficiency Syndrome, Immunoglobulin G, CD4-Positive T-Lymphocytes, Enzyme-Linked Immunosorbent Assay, Vaccines, Immunization, 23-valent pneumococcal capsular polysaccharide vaccine, Adult, immunology, ICA11

960707
WeB115